Inside Belite Bio: Advancing Hope for Stargardt Disease
Join us for an exclusive webinar presented by Belite Bio, a clinical stage biopharmaceutical drug company focused on novel therapeutics for retinal degenerative eye diseases. This session will feature Dr. Hendrik Scholl, Chief Medical Officer at Belite Bio, a globally recognized expert in Stargardt disease and inherited retinal conditions, with extensive experience in both academic research and clinical development. Dr. Scholl will share research updates on Stargardt disease—including Belite Bio’s DRAGON II study, a multi-national clinical trial for individuals living with Stargardt.
Event Details
Date: Thursday, August 21, 2025
Time: 12:00 – 1:00 PM EST
Location: Zoom – link provided upon registration
Cost: Free
This session will cover:
- What’s on the horizon for Stargardt disease
- Study design and its potential impact
- Who may be eligible—and how screening works
- What participants can expect throughout the trial
- Key clinical milestones so far
Whether you’re living with Stargardt, supporting someone who is, or working in the field, this is your opportunity to learn, engage, and ask questions directly from the Belite Bio team.
This webinar will be recorded and made available on our YouTube channel after the event. Make sure to subscribe to receive a notification when the recording is available!
Contact Information
If you have any questions or need help registering, please email development@carroll.org.
